Oncology Pipeline: Exciting Breakthroughs Cited at AMCP Nexus 2024
Fully 1,600 cancer treatments and vaccines are in development, according to speakers at an AMCP Nexus 2024 presentation, in Las Vegas.
Related Articles
AACR IO
AACR IO: Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy
First Clinical Trial of “Memory Like” Natural Killer Cells in Ovarian Cancer Opens at Dana-Farber
Investigators are opening a trial to evaluate a novel type of immune cellular therapy in patients with recurrent, platinum-resistant ovarian cancer.
Eric Topol (@erictopol.bsky.social)
A mechanism for why durable weight loss is so difficult: epigenetic memory of fat cells https://www.nature.com/articles/s41586-024-08165-7
Plenary Lecture to untangle drivers of racial disparities in breast cancer – SABCS Meeting News
Melissa Davis, PhD, will deliver a plenary lecture during the 2024 San Antonio Breast Cancer Symposium® about the social and biological drivers that underlie racial…
Events
Huntsman Cancer Institute at the University of Utah holds events for patients, families, caregivers, donors, and friends. We also sponsor conferences and seminars on topics…
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally…
Home Page: Annals of Oncology
Published online: September 14, 2024 Annals of Oncology, the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, provides…
Volume 84 Issue 22_Supplement | Cancer Research | American Association for Cancer Research
Cancer Research | 84 | 22_Supplement | November 2024
The Targeted Pulse: Discover Upcoming Meetings, FDA Action, and Key Insights in SCLC and mCSPC
The 22nd Annual Winter Lung Cancer Conference® will explore advances in neoadjuvant/adjuvant therapies. The FDA has approved Obe-cel for R/R B-ALL, and new treatments in…
Mirdametinib Boosts Outcomes, QOL in NF1-PN
Mirdametinib led to confirmed responses and meaningful pain and health-related quality of life improvements in both children and adults with neurofibromatosis type 1-associated PNs.
